Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mitoxantrone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | NSD2 | O96028 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 1.00 |
| ▸ | CSNK2B | P67870 | 3/20 | 1.00 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 1.00 |
| ▸ | CSNK2A3 | Q8NEV1 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mitoxantrone SCHEMBL20214110 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| SCHEMBL11038495 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| SCHEMBL11036806 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Mitoxantrone SCHEMBL3000 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| SCHEMBL11517949 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| SCHEMBL11391594 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Mitoxantrone SCHEMBL29720597 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| SCHEMBL11041207 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Mitoxantrone SCHEMBL2342900 | 0.98 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA | |
| Hydrochloric Acid SCHEMBL10522176 | 0.98 | MEN1 (1.00) | MEN1KMT2AMAPK1TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 548 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20260028309-A1 | POLYMORPHIC FORMS OF RAD1901-2HCL | RADIUS PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | claimed |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2025-11-06 | — | — | US | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-4608505-A1 | ANTIOXIDANT COMPOSITIONS AND METHODS OF USE | Sanare Pharmaceuticals Corporation (US) | 2025-09-03 | — | — | EP | claimed |
| US-12398094-B2 | Polymorphic forms of RAD1901-2HCL | RADIUS PHARMACEUTICALS, INC. (US) | 2025-08-26 | — | — | US | claimed |
| US-12247206-B2 | Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-03-11 | — | — | US | claimed |
| EP-4081553-A1 | CHIMERIC ANTIGEN RECEPTORS THAT BIND TO PROSTATE SPECIFIC MEMBRANE ANTIGEN | Albert-Ludwigs-Universität Freiburg (DE) | 2022-11-02 | — | — | EP | claimed |
| US-20220313836-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-10-06 | — | — | US | claimed |
| CN-115117467-A | Acid water system all-organic symmetrical battery based on dihydroxynaphthalene dione derivative | 常州大学 | 2022-09-27 | — | — | CN | claimed |
| US-20220249594-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2022-08-11 | — | — | US | claimed |
| CN-114869858-A | Nucleic acid-chemotherapeutic drug complex nanoparticle coated with homologous cancer cell membrane | 上海交通大学 | 2022-08-09 | — | — | CN | claimed |
| EP-3986463-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| EP-3986476-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| WO-2022078524-A2 | SPECIFIC CONJUGATION OF AN ANTIBODY | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-04-21 | — | — | WO | claimed |
| US-20220096518-A1 | COMPOSITIONS AND METHODS FOR CANCER THERAPY | AIM IMMUNOTECH INC. (US) | 2022-03-31 | — | — | US | claimed |
| US-20220048848-A1 | POLYMORPHIC FORMS OF RAD1901-2HCL | RADIUS HEALTH, INC. | 2022-02-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048848-A1 | POLYMORPHIC FORMS OF RAD1901-2HCL | RAD50, RAD1, RAD54L | TOP2A 76/4885MEN1 3184/4885KMT2A 1874/4885 |
| US-20250339551-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | FCGR2A, FCGR3B, FCGR1A | TOP2A 1307/4885MEN1 287/4885KMT2A 443/4885 |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | TOP2A 3964/4885MEN1 104/4885KMT2A 3390/4885 |
| US-20220313836-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | CD2BP2, DCLRE1A, EPCAM | TOP2A 211/4885MEN1 2291/4885KMT2A 3090/4885 |
| US-20260028309-A1 | POLYMORPHIC FORMS OF RAD1901-2HCL | BRCA1, TP53, RAD1 | TOP2A 66/4885MEN1 3007/4885KMT2A 1365/4885 |
| US-20260138987-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM5, CHRM3 | TOP2A 3874/4885MEN1 1785/4885KMT2A 1878/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | TOP2A 156/4885MEN1 2393/4885KMT2A 3633/4885 |
| US-20220249594-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | CD4, TEKT1, NTSR1 | TOP2A 4031/4885MEN1 27/4885KMT2A 3080/4885 |
| US-12398094-B2 | Polymorphic forms of RAD1901-2HCL | RAD50, RAD1, RAD54L | TOP2A 76/4885MEN1 3184/4885KMT2A 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.